PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

Pancreatic adenocarcinoma (PDAC) is a major unmet medical need and a deeper understanding of molecular drivers is needed to advance therapeutic options for patients. We report here that p21‐activated kinase 1 (PAK1) is a central node in PDAC cells downstream of multiple growth factor signalling pathways, including hepatocyte growth factor (HGF) and MET receptor tyrosine kinase. PAK1 inhibition blocks signalling to cytoskeletal effectors and tumour cell motility driven by HGF/MET. MET antagonists, such as onartuzumab and crizotinib, are currently in clinical development. Given that even highly effective therapies have resistance mechanisms, we show that combination with PAK1 inhibition overcomes potential resistance mechanisms mediated either by activation of parallel growth factor pathways or by direct amplification of PAK1. Inhibition of PAK1 attenuated in vivo tumour growth and metastasis in a model of pancreatic adenocarcinoma. In human tissues, PAK1 is highly expressed in a proportion of PDACs (33% IHC score 2 or 3; n = 304) and its expression is significantly associated with MET positivity (p < 0.0001) and linked to a widespread metastatic pattern in patients (p = 0.067). Taken together, our results provide evidence for a functional role of MET/PAK1 signalling in pancreatic adenocarcinoma and support further characterization of therapeutic inhibitors in this indication. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd

[1]  T. Jin,et al.  p21-Activated protein kinases and their emerging roles in glucose homeostasis. , 2014, American journal of physiology. Endocrinology and metabolism.

[2]  I. Wistuba,et al.  Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit , 2014, Clinical Cancer Research.

[3]  R. Govindan,et al.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. V. Vande Woude,et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent , 2013, Proceedings of the National Academy of Sciences.

[5]  Luis E. Arias-Romero,et al.  Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. , 2013, Cancer research.

[6]  A. Harris,et al.  P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. , 2013, Journal of the National Cancer Institute.

[7]  Thomas D. Wu,et al.  Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events , 2012, Genome research.

[8]  A. Jubb,et al.  p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. , 2012, Cancer research.

[9]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[10]  D. Wazer,et al.  New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma. , 2012, JOP : Journal of the pancreas.

[11]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[12]  Da-Qiang Li,et al.  Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations , 2012, Clinical Cancer Research.

[13]  M. Belvin,et al.  Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes , 2012, PloS one.

[14]  G. Kristiansen,et al.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma , 2012, Nature.

[15]  J. Field,et al.  PAK signaling in cancer , 2012, Cellular logistics.

[16]  T. Welling,et al.  c-Met is a marker of pancreatic cancer stem cells and therapeutic target. , 2011, Gastroenterology.

[17]  P. Hegde,et al.  Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. , 2011, Cancer discovery.

[18]  J. Chernoff,et al.  Inhibition or Ablation of p21-activated Kinase (PAK1) Disrupts Glucose Homeostatic Mechanisms in Vivo* , 2011, The Journal of Biological Chemistry.

[19]  Todd R. Golub,et al.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling , 2011, Oncogene.

[20]  A. Maitra,et al.  Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer , 2011, PloS one.

[21]  A. Harris,et al.  Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells , 2011, Proceedings of the National Academy of Sciences.

[22]  J. Reis-Filho,et al.  β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation , 2011, Modern Pathology.

[23]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[24]  G. Shapiro,et al.  Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. , 2010, Current opinion in investigational drugs.

[25]  J. Masters,et al.  PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion , 2010, Journal of Cell Science.

[26]  A. Ridley,et al.  PAK1 and PAK2 have different roles in HGF-induced morphological responses. , 2009, Cellular signalling.

[27]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Baldwin,et al.  PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins. , 2008, Biochimica et biophysica acta.

[29]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[30]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[31]  S. Deacon,et al.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. , 2008, Chemistry & biology.

[32]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[33]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[34]  M. Westphal,et al.  A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo , 2006, Clinical Cancer Research.

[35]  R Smits,et al.  Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia , 2006, Oncogene.

[36]  D. Pardoll,et al.  Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. , 2006, Cancer research.

[37]  E. Rosen,et al.  Role of NF-κB signaling in hepatocyte growth factor/scatter factor-mediated cell protection , 2005, Oncogene.

[38]  S. Batra,et al.  Neural Invasion in the Staging of Pancreatic Cancer , 2003, Pancreas.

[39]  K. Herzig,et al.  Expression of hepatocyte growth factor, keratinocyte growth factor and their receptors in experimental chronic pancreatitis , 2001, European journal of clinical investigation.

[40]  K. Kaibuchi,et al.  Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. , 2000, Molecular biology of the cell.

[41]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[42]  S. Ohwada,et al.  Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin‐1α stimulation , 1998, International journal of cancer.

[43]  R. Poulsom,et al.  Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. , 1995, Cancer research.

[44]  Mark Merchant,et al.  Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. , 2012, Cancer research.

[45]  A. Whale,et al.  Signalling to cancer cell invasion through PAK family kinases. , 2011, Frontiers in bioscience.

[46]  D. Pardoll,et al.  Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases , 2003, Annals of Surgical Oncology.